{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:27:39Z","timestamp":1715992059885},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,11,28]],"date-time":"2012-11-28T00:00:00Z","timestamp":1354060800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s10620-012-2484-x","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T15:55:04Z","timestamp":1354204504000},"page":"1371-1382","source":"Crossref","is-referenced-by-count":7,"title":["Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin"],"prefix":"10.1007","volume":"58","author":[{"given":"A.","family":"Andriulli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Iacobellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. R.","family":"Valvano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Spirito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bossa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Niro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,28]]},"reference":[{"key":"2484_CR1","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","volume":"360","author":"Ch Hezode","year":"2011","unstructured":"Hezode Ch, Forrestier N, Dusheiko G, et al. Telaprevir and Peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2011;360:1839\u20131850.","journal-title":"N Engl J Med"},{"key":"2484_CR2","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405\u20132416.","journal-title":"N Engl J Med"},{"key":"2484_CR3","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordard","year":"2011","unstructured":"Poordard F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195\u20131206.","journal-title":"N Engl J Med"},{"key":"2484_CR4","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","volume":"339","author":"JG McHutchison","year":"1998","unstructured":"McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485\u20131492.","journal-title":"N Engl J Med"},{"key":"2484_CR5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(97)06088-1","volume":"351","author":"O Reichard","year":"1998","unstructured":"Reichard O, Norkrans G, Fryden A, et al. Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet. 1998;351:83\u201387.","journal-title":"Lancet"},{"key":"2484_CR6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958\u2013965.","journal-title":"Lancet"},{"key":"2484_CR7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2b plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975\u2013982.","journal-title":"N Engl J Med"},{"key":"2484_CR8","first-page":"1100","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced vial clearance. Nature. 2009;461:1100\u20131104.","journal-title":"Nature"},{"key":"2484_CR9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2005.04.009","volume":"43","author":"P Ferenci","year":"2005","unstructured":"Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kd)\/ribavirin. J Hepatol. 2005;43:425\u2013433.","journal-title":"J Hepatol"},{"key":"2484_CR10","first-page":"950","volume":"43","author":"DM Jensen","year":"2006","unstructured":"Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24\u00a0weeks peginterferon alpha-2a (40 kd)\/ribavirin. Hepatology. 2006;43:950\u2013954.","journal-title":"Hepatology"},{"key":"2484_CR11","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/hep.24458","volume":"54","author":"A Mangia","year":"2011","unstructured":"Mangia A, Thompson AJ, Santoro R, et al. Limited utility of IL28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology. 2011;54:772\u2013780.","journal-title":"Hepatology"},{"key":"2484_CR12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/hep.24480","volume":"54","author":"V Martino Di","year":"2011","unstructured":"Di Martino V, Richou C, Cervoni JP, et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized controlled trials and implications for the future. Hepatology. 2011;54:789\u2013800.","journal-title":"Hepatology"},{"key":"2484_CR13","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/hep.20212","volume":"39","author":"LJ Jeffers","year":"2004","unstructured":"Jeffers LJ, Cassidy W, Howell CD, et al. Peginterferon alfa-2b (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39:1702\u20131708.","journal-title":"Hepatology"},{"key":"2484_CR14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/9780470743386.ch16","volume-title":"Identifying and Quantifying Heterogeneity in Introduction to Meta-analysis","author":"M Borenstein","year":"2009","unstructured":"Borenstein M, Hedges VH, Higgins JPT, et al. Identifying and Quantifying Heterogeneity in Introduction to Meta-analysis. Chichester UK: Wiley; 2009:107\u2013113."},{"key":"2484_CR15","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u20131558.","journal-title":"Stat Med"},{"key":"2484_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.epirev.a036298","volume":"9","author":"S Greenland","year":"1987","unstructured":"Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1\u201330.","journal-title":"Epidemiol Rev"},{"key":"2484_CR17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/sim.1040","volume":"21","author":"HC Houwelingen van","year":"2002","unstructured":"van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002;21:589\u2013624.","journal-title":"Stat Med"},{"key":"2484_CR18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u2013634.","journal-title":"BMJ"},{"key":"2484_CR19","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088\u20131101.","journal-title":"Biometrics"},{"key":"2484_CR20","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/hep.23073","volume":"50","author":"Y Benhamou","year":"2009","unstructured":"Benhamou Y, Afdhal NH, Nelson DR, et al. A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-na\u00efve patients with chronic hepatitis C: ViSer1 results. Hepatology. 2009;50:717\u2013726.","journal-title":"Hepatology"},{"key":"2484_CR21","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/j.gastro.2006.02.015","volume":"130","author":"T Berg","year":"2006","unstructured":"Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72\u00a0weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130:1086\u20131097.","journal-title":"Gastroenterology"},{"key":"2484_CR22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.biopha.2011.03.004","volume":"65","author":"R Bonardi","year":"2011","unstructured":"Bonardi R, Tabone M, Manca A, et al. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin. Biomed Pharmacother. 2011;65:303\u2013306.","journal-title":"Biomed Pharmacother"},{"key":"2484_CR23","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2893.2006.00758.x","volume":"13","author":"C Brand\u0101o","year":"2006","unstructured":"Brand\u0101o C, Barone A, Carrilho F, et al. The results of a randomized trial looking at 24\u00a0weeks vs 48\u00a0weeks of treatment with peginterferon \u03b1-2a (40\u00a0kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1. J Viral Hepat. 2006;13:552\u2013559.","journal-title":"J Viral Hepat"},{"key":"2484_CR24","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/hep.23816","volume":"52","author":"M Buti","year":"2010","unstructured":"Buti M, Zakharova NG, Blokhina NP, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72\u00a0weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology. 2010;52:1201\u20131207.","journal-title":"Hepatology"},{"key":"2484_CR25","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1053\/j.gastro.2006.06.008","volume":"131","author":"HS Conjeevaram","year":"2006","unstructured":"Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470\u2013477.","journal-title":"Gastroenterology"},{"key":"2484_CR26","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2893.2007.00862.x","volume":"14","author":"A Bisceglie Di","year":"2007","unstructured":"Di Bisceglie A, Ghalib RH, Hamzeh FM, et al. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hep. 2007;14:721\u2013729.","journal-title":"J Viral Hep"},{"key":"2484_CR27","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1440-1746.2008.05397.x","volume":"23","author":"A Escudero","year":"2008","unstructured":"Escudero A, Rodriguez F, Serra MA. del et al. Pegylated \u03b1-interferon-2a plus ribavirin compared with pegylated \u03b1-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. J Gastroenterol Hepatol. 2008;23:861\u2013866.","journal-title":"J Gastroenterol Hepatol"},{"key":"2484_CR28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2008.04.015","volume":"135","author":"P Ferenci","year":"2008","unstructured":"Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2b and ribavirin for 24\u00a0weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135:451\u2013458.","journal-title":"Gastroenterology"},{"key":"2484_CR29","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/hep.22448","volume":"48","author":"M Fried","year":"2008","unstructured":"Fried M, Jensen DM, Rodriguez-Torres M, et al. Improved outcome in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon \u03b1-2b and ribavirin. Hepatology. 2008;48:1033\u20131043.","journal-title":"Hepatology"},{"key":"2484_CR30","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jhep.2009.07.008","volume":"51","author":"A Grasso","year":"2009","unstructured":"Grasso A, Malfatti F, De Leo P, et al. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol. 2009;51:984\u2013990.","journal-title":"J Hepatol"},{"key":"2484_CR31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis SJ, Sette HJ, Morgan TR, et al. Peginterferon- alpha2a (40KD) and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346\u2013355.","journal-title":"Ann Intern Med"},{"key":"2484_CR32","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1086\/650470","volume":"201","author":"CF Huang","year":"2010","unstructured":"Huang CF, Yang JF, Dai CY, et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis. 2010;201:751\u2013759.","journal-title":"J Infect Dis"},{"key":"2484_CR33","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ajg.2008.60","volume":"104","author":"T Ide","year":"2009","unstructured":"Ide T, Hino T, Ogata K, et al. A randomized study of extended treatment with peginterferon \u03b1-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol. 2009;104:70\u201375.","journal-title":"Am J Gastroenterol"},{"key":"2484_CR34","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1872-034X.2009.00523.x","volume":"39","author":"H Ikeda","year":"2009","unstructured":"Ikeda H, Suzuki M, Okuse C, et al. Short-term prolongation of pegylated interferon and ribavirin for genotype 1b chronic hepatitis C patients with early viral response. Hepatol Res. 2009;39:733\u2013759.","journal-title":"Hepatol Res"},{"key":"2484_CR35","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","volume":"376","author":"PY Kwo","year":"2010","unstructured":"Kwo PY, McCone J, Schiff ER, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa and ribavirin in treatment-na\u00efve patients with genotype 1 hepatitis C infection \u201c(SPRINT-1): an open-label, randomised, multicenter phase 2-trial. Lancet. 2010;376:705\u2013716.","journal-title":"Lancet"},{"key":"2484_CR36","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1086\/592579","volume":"47","author":"CH Liu","year":"2008","unstructured":"Liu CH, Liu CJ, Liang CC, et al. Pegylated interferon \u03b1-2a plus ribavirin for treatment-na\u00efve Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis. 2008;47:1260\u20131269.","journal-title":"Clin Infect Dis"},{"key":"2484_CR37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hep.22061","volume":"47","author":"A Mangia","year":"2008","unstructured":"Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology. 2008;47:43\u201350.","journal-title":"Hepatology"},{"key":"2484_CR38","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","volume":"361","author":"JG McHutchison","year":"2009","unstructured":"McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580\u2013593.","journal-title":"N Engl J Med"},{"key":"2484_CR39","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","volume":"360","author":"JG McHutchison","year":"2009","unstructured":"McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New Engl J Med. 2009;360:1827\u20131838.","journal-title":"New Engl J Med"},{"key":"2484_CR40","first-page":"213","volume":"3","author":"K Mimidis","year":"2006","unstructured":"Mimidis K, Papadopoulos VP, Elefsiniotis I, et al. Hepatitis C survival curve analysis in na\u00efve patients treated with peginterferon \u03b1-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data. J Gastroint Liver Dis. 2006;3:213\u2013219.","journal-title":"J Gastroint Liver Dis"},{"key":"2484_CR41","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1365-2893.2007.00944.x","volume":"15","author":"N Napoli","year":"2008","unstructured":"Napoli N, Giannelli G, Antonaci A, et al. The use of different peg-interferon \u03b1-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response. J Viral Hep. 2008;15:300\u2013304.","journal-title":"J Viral Hep"},{"key":"2484_CR42","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s00535-009-0008-z","volume":"44","author":"H Nomura","year":"2009","unstructured":"Nomura H, Miyahi Y, Tanimoto H, et al. Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices. J Gastroenterol. 2009;44:338\u2013345.","journal-title":"J Gastroenterol"},{"key":"2484_CR43","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.23827","volume":"52","author":"F Poordard","year":"2010","unstructured":"Poordard F, Lawitz E, Shiffman ML, et al. Virologic response rates of weight-based taribavirin versus ribavirin in treatment na\u00efve patients with genotype 1 chronic hepatitis C. Hepatology. 2010;52:1208\u20131215.","journal-title":"Hepatology"},{"key":"2484_CR44","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1053\/j.gastro.2010.08.051","volume":"139","author":"KR Reddy","year":"2010","unstructured":"Reddy KR, Shiffman ML, Rodriguez-Torres M, et al. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. Gastroenterology. 2010;139:1972\u20131983.","journal-title":"Gastroenterology"},{"key":"2484_CR45","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/hep.23130","volume":"50","author":"SK Roberts","year":"2009","unstructured":"Roberts SK, Weltman MD, Crawford DHG, et al. Impact of high-dose peginterferon alfa-2a on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology. 2009;50:1045\u20131055.","journal-title":"Hepatology"},{"key":"2484_CR46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJMoa0805062","volume":"360","author":"M Rodriguez-Torres","year":"2009","unstructured":"Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med. 2009;360:257\u2013267.","journal-title":"N Engl J Med"},{"key":"2484_CR47","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2009.08.071","volume":"138","author":"MG Rumi","year":"2010","unstructured":"Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-\u03b12a plus ribavirin vs peginterferon-\u03b12b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010;138:108\u2013115.","journal-title":"Gastroenterology"},{"key":"2484_CR48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2006.05.016","volume":"131","author":"JM S\u00e1nchez-Tapias","year":"2006","unstructured":"S\u00e1nchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 vs 72\u00a0weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131:451\u2013460.","journal-title":"Gastroenterology"},{"key":"2484_CR49","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1365-2036.2007.03451.x","volume":"26","author":"G Sebastiani","year":"2007","unstructured":"Sebastiani G, Ferrari A, Boccato S, et al. Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV-1 positive patients with chronic hepatitis C. Aliment Pharmacol Ther. 2007;26:1077\u20131082.","journal-title":"Aliment Pharmacol Ther"},{"key":"2484_CR50","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/hep.22319","volume":"47","author":"ML Yu","year":"2008","unstructured":"Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008;47:1884\u20131893.","journal-title":"Hepatology"},{"key":"2484_CR51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jhep.2005.10.003","volume":"44","author":"S Zeuzem","year":"2006","unstructured":"Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24\u00a0weeks treatment with Peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pre-treatment viremia. J Hepatol. 2006;44:97\u2013103.","journal-title":"J Hepatol"},{"key":"2484_CR52","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2010.06.066","volume":"139","author":"S Zeuzem","year":"2010","unstructured":"Zeuzem S, Sulkowski MS, Lawitz EJ, et al. Albinterferon alfa-2b was not inferior to pegylated interferon-\u03b1 in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology. 2010;139:1257\u20131266.","journal-title":"Gastroenterology"},{"key":"2484_CR53","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2893.2009.01157.x","volume":"17","author":"M Rodriguez-Torres","year":"2010","unstructured":"Rodriguez-Torres M, Sulkowski MS, Chung RT, et al. Factors associated with rapid and early virologic response to peginterferon alfa-2b\/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hep. 2010;17:139\u2013147.","journal-title":"J Viral Hep"},{"key":"2484_CR54","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1365-2893.2009.01122.x","volume":"16","author":"KR Reddy","year":"2009","unstructured":"Reddy KR, Messinger D, Popescu M, et al. Peginterferon alfa-2a (40\u00a0kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hep. 2009;16:724\u2013731.","journal-title":"J Viral Hep"},{"key":"2484_CR55","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1111\/j.1365-2893.2010.01402.x","volume":"18","author":"AJ Muir","year":"2011","unstructured":"Muir AJ, Hu KQ, Gordon SC, et al. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hep. 2011;18:e134\u2013e143.","journal-title":"J Viral Hep"},{"key":"2484_CR56","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jhep.2010.04.024","volume":"53","author":"WSC Cheng","year":"2010","unstructured":"Cheng WSC, Roberts SK, McGaughan G, et al. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic response. J Hepatol. 2010;53:616\u2013623.","journal-title":"J Hepatol"},{"key":"2484_CR57","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","volume":"365","author":"KE Sherman","year":"2011","unstructured":"Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014\u20131024.","journal-title":"N Engl J Med"},{"key":"2484_CR58","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","volume":"54","author":"MG Ghany","year":"2011","unstructured":"Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433\u20131444.","journal-title":"Hepatology"},{"key":"2484_CR59","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cgh.2010.07.019","volume":"9","author":"AF St\u00e4ttermayer","year":"2011","unstructured":"St\u00e4ttermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-na\u00efve patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9:344\u2013350.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2484_CR60","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1478-3231.2010.02389.x","volume":"31","author":"JG McHutchison","year":"2011","unstructured":"McHutchison JG. The role of genetic markers in hepatitis C therapy: a major step for individualized care. Liver Int. 2011;31:29\u201335.","journal-title":"Liver Int"},{"key":"2484_CR61","unstructured":"Boceprevir EU Summary of Product Characteristics [online]. Available at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_information\/Human\/002332\/WC500109786.pdf . Accessed on 19 November 2011."},{"key":"2484_CR62","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","volume":"139","author":"AJ Thompson","year":"2010","unstructured":"Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest predictor of sustained virologic response in genotype 1 Hepatitis C Virus. Gastroenterology. 2010;139:120\u2013129.","journal-title":"Gastroenterology"},{"key":"2484_CR63","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/0003-4819-156-4-201202210-00005","volume":"156","author":"S Liu","year":"2012","unstructured":"Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156:279\u2013290.","journal-title":"Ann Intern Med"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-012-2484-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-012-2484-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-012-2484-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T05:08:16Z","timestamp":1714626496000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-012-2484-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,28]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["2484"],"URL":"https:\/\/doi.org\/10.1007\/s10620-012-2484-x","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,28]]}}}